1/60
Looks like no tags are added yet.
What is IBD
A group of inflammatory conditions of the GI tract, mainly in the colon and small intestine
2 types of IBD
UC and CD
Shared features of UC and CD
Uknown etiology
Inflammation related
More common in western societies
Low frequency among non-whites
Both sexes affected equally
Usually affect people before the age of 40
Tend to occur in the same families
Different features of UC and CD
Incidence of UC is static whereas CD is increasing
Only the colon is affected in UC but CD can affect the entire GI tract
UC is superficial and affects Continuous areas
CD affects deep tissue with skip lesions
With CD fistula and fissure formation is possible
Idiopathic disease
Means the cause is unknown
Treatment target
Symptoms
Risk factors for IBD
Genetics, infection, immunological, environmental
Defenses of the Intestine
Mucus
Peyer’s patch and M cells
Paneth Cells
Macrophages, granulocytes, DC, T and B cells
Microflora
Epithelial Cells
Role of macrophages in IBD
When macrophages have a NOD2 defect they can become infected. This leads to chronic T cell stimulation by the infected macrophages resulting in inflammation.
NOD 2
Nucleotide binding Oligomerization domain containing 2
Recognizes molecules containing specific structures that are found in bacteria.
Expressed in macrophages, APC, epithelial cells, endothelial cells and T cells
Defective Epithelial Cell Response in IBD
In IBD the structure of GI epithelium changes, leading to gaps between cells. This leads to a loss in barrier function and increased exposure to the mucosal microflora. This leads to increased effector response and inflammation.
Normal epithelial Resposnes
Normal epithelium is tightly packed cells. These cells can be activated to produce defensins which protect against the microflora as well as chemokines.
Defects in antigen presenting cells in IBD
NOD2 defect can lead to the inappropriate activation of APCs. This causes disruption of the homeostatic balance of effector and regulatory cells

Which cytokines are pro-inflammatory
IL-1,2,8,12
TNFa and IFN
Which cytokines are anti-inflammatory
IL-10
Regulatory
Suppresses immunoresponse
Tumor Necrosis Factor Alpha
The central cytokine for IBD. The primary target for existing therapies.
Effects of TNF-a activation
Increases lymphocyte recruitment
Increases endothelial activation (adhesion molecules, permeability)
Increases neutrophil recruitment
TNF-a effect on intestinal epithelium
Increases keratinocyte growth factor, epidermal growth factor, MHC class 1 + 2, matrix metalloproteinase
TNF-a effect on endothelium
Increases adhesion molecules, selecting, VCAM, ICAM
TNF-a effect on macrophages
Increase IL-12, granulocyte macrophage colony stimulating factor, IL-6
TNF-a effect on neutrophils
Increases recruitment, activation, and delays apoptosis
TNF-a effect on lymphocytes
Increases recruitment, activation, and delays apoptosis
Intracellular adhesion molecule-1
Normally expressed in high levels on endothelial cells and leukocyte.
Induced by IL-1 and TNFa
A ligand for LFA-1, receptor found on leukocytes
When activated, leukocytes bind to endothelial cells via ICAM/LFA and then transmigrated into tissue
Objectives for IBD treatment include
Alleviate the disease and symptoms
Maintain remission
Overview of IBD treatment
Pharmacological - anti-inflammatory and immunosuppressive agents
Surgery
Antioxidants
Bacterial recolonization (probiotics)
Helminthic therapy
Herbal/Dietary modifications
Antibiotics
Groups of pharmacological therapies
Anti-inflammatory drugs: NSAID, corticosteroids, adrenocorticotropic hormone
Immunosuppressive therapies: chemical and biological
Combination therapies of both, usually want to pick drugs with different MOAs
Aminosalicylates
Non-Steroidal Anti-Inflammatory drug
Active ingredient is 5-aminosalicylic acid (5-ASA)
Has poor intestine absorption so it provides topical relief within the intestine
Formulations of 5-ASA
Mesalamine - 5-ASA
Sulfasalazine, Balazide, Olsalazine - Release 5-ASA by resident bacteria in terminal ileum and colon
Amino salicylates mechanism of action
They inhibit LOX and COX in the Arachidonic acid cascade preventing the production of leukotrienes and prostaglandins that normally lead to inflammation
Corticosteroid MOA transactivation
Corticosteroids diffuse across the cell membrane due to their lipid solubility.
Bind to cytoplasmic glucocorticoid receptors (GR).
The corticosteroid-GR complex moves into the nucleus.
Complex binds to glucocorticoid response elements (GREs) on DNA.
Recruits coactivator proteins (GRIP-1, CBP, pCAF, and HAT).
HAT adds acetyl groups to histones, loosening DNA packaging.
Increases transcription of anti-inflammatory genes.
Produces anti-inflammatory proteins (Annexin-1, SLPI, MKP-1, IκB-α, GILZ).
These proteins suppress inflammatory pathways, reducing inflammation.
Corticosteroids MOA trans repression
Inflammatory stimuli (e.g., IL-1β and TNF-α) activate the IKK-2 pathway.
IKK-2 activates NF-κB (p65/p50), allowing it to move into the nucleus.
NF-κB recruits coactivators (CBP, pCAF, and HAT), promoting histone acetylation.
Histone acetylation increases transcription of pro-inflammatory genes.
Corticosteroids diffuse across the cell membrane and bind cytoplasmic glucocorticoid receptors (GR).
The corticosteroid-GR complex enters the nucleus and interacts with NF-κB.
GR recruits HDAC2 (histone deacetylase 2), which removes acetyl groups from histones.
Deacetylation tightens DNA packaging, reducing transcription of pro-inflammatory genes.
Production of inflammatory cytokines, chemokines, adhesion molecules, and inflammatory enzymes decreases.
Corticosteroid trans activation of anti-inflammatory molecules
Increased production of:
Annexis-1
SLPI (secretory Leukoprotease inhibitor)
MKP-1 (mitogen-activated kinase phosphatase-1)
IkBa (inhibitor of NF-kB)
GILZ (glucocorticoid-induced leucine zipper protein)
Corticosteroid trans repression of inflammatory molecules
Decrease production of:
Cytokines
Chemokines
Adhesion molecules
Inflammatory enzymes
Inflammatory receptors
Inflammatory proteins
Corticosteroid cis-repression
This is what leads to negative side effects
Decreases production of
POMC (proopiomelanocortin)
CRF-1 (corticotrophin releasing factor)
Osteocalcin
Keratin
Cortisol
The bodies natural glucocorticoid that produces anti-inflammatory and immunosuppressive effects. Has same MOA.
HPA Axis (hypothalamic-pituitary-adrenal)
The hypothalamus releases corticotropic releasing hormone (CRH)
In response the anterior pituitary gland releases ACTH
ACTH stimulate the adrenal cortex to increase release of cortisol
Examples of purine analogs
Immunosuppressives
Azathioprine and 6-mercaptopurine
MOA of purine analogs
Azathioprine is converted into 6-mercaptopurine (6-MP).
6-MP acts as a purine analog.
Interferes with normal purine synthesis via ribose phosphate
Decreases production of purine nucleotides (ATP and GTP).
Reduces DNA and RNA synthesis.
Inhibits proliferation of cells, especially leukocytes.
Produces an immunosuppressive effect.
Cyclosporine MOA
-
Chemical immunosuppressives
Purine analogs
Cyclosporine - calcineurin inhibitor
Methotrexate
MMP inhibitors
TNFa antagonists
Cyclosporine MOA
Cyclosporine enters the T cell.
Binds to a protein called cyclophilin.
Forms a cyclosporine-cyclophilin complex.
The complex inhibits calcineurin.
Calcineurin can no longer activate NFATc.
Decreases IL-2 gene expression.
Decreases T-cell growth, differentiation, and activation.
Produces immunosuppression.
Methotrexate MOA
Methotrexate produces effects involving folate and adenosine pathways.
Suppresses T-cell activation.
Decreases ICAM-1 expression.
Promotes apoptosis of activated T cells.
Reduces immune activity and inflammation.
MMP MOA
MMPs are enzymes that require zinc for their activity.
MMP inhibitors bind/chelate zinc at the MMP catalytic site.
Zinc is removed from the catalytic site.
MMP activity is inhibited.
Conversion of membrane-bound TNF-α into free TNF-α is reduced.
Decreases this source of soluble TNF-α and inflammatory signaling
Which drugs are TNFa antagonists
Infliximab
Adalimumab
Etanercept
Certolizumab
New generation of TNFa antagonist: Golimumab
Fourth generation of TNFa antagonist
Fully humanized mAb with high affinity for TNFa
Better safety profile
Approved in 2014 for UC
MOA of integrin antagonist: Natalizumab
Natalizumab binds to α4 integrin on leukocytes.
Blocks α4 integrin interactions with VCAM-1 and MAdCAM-1.
Prevents leukocytes from adhering properly to endothelial cells.
Decreases leukocyte migration into intestinal tissue.
Reduces intestinal inflammation.
Natalizumab (Tysabri)
A humanized mAb
Targeting to a4 integrin complex with B1 or B7 subunit
CDR grafted from murine Ab
Vedolizumab MOA
Selectively prevent leukocyte migration into the GI tract.
Vedolizumab binds specifically to α4β7 integrin.
Blocks the interaction between α4β7 integrin and MAdCAM-1.
Prevents leukocytes from migrating into GI tissue.
Reduces intestinal inflammation.
Vedolizumab (Entyvio)
New generation of integrin antagonist
Specific a4B7
Approved in 2014 for both CD and UC
Ustekinumab MOA
Binds the common p40 subunit shared by IL-12 and IL-23.
Prevents IL-12 and IL-23 from carrying out their inflammatory signaling.
Decreases cytokine-mediated immune activation.
Reduces inflammation.
Approved for both CD and UC. Positive results in treating CD patients who failed anti TNFa therapy
Risankizumab
Binds the IL-23A subunit.
Prevents IL-23 from carrying out its inflammatory signaling.
Decreases IL-23-mediated immune activity.
Reduces inflammation.
Approved for Crohn’s
Ozanimod
Is a sphingosine-1-phosphate receptor modulator (agonist)
approved for UC
S1P is expressed on T and NK cells
By binding to S1P1 it reduces the number of T cells in circulation from lymph nodes
Ozanimod MOA
Ozanimod binds to S1P receptors (S1P1 and S1P5).
Binding to S1P1 causes receptor internalization.
Prevents normal lymphocyte movement from lymph nodes into circulation.
Sequesters lymphocytes in peripheral lymphoid organs.
Decreases the number of circulating lymphocytes available to enter inflamed intestinal tissue.
Reduces intestinal inflammation.
JAK inhibitors - small molecules
Upadacitinib and Tofacitinib
JAKis MOA
Tofacitinib or upadacitinib inhibits JAK activity.
Prevents normal JAK-mediated activation of STAT.
Decreases intracellular inflammatory signaling.
Reduces expression of immune and inflammation-related responses.
Produces immunosuppressive and anti-inflammatory effects.
Antioxidants
A metabolic defect leads to the accumulation of hydroxyl and other radicals beneath the cell membrane.
These radicals damage cellular membranes.
Membrane destruction contributes to ulcerative colitis.
Antioxidants may help neutralize these damaging radicals.
This may protect cell membranes from oxidative damage.
What is a probiotic
Live microorganism which when administered in adequate amount confer a health benefit on the host. Examples include certain yeasts, lactic acid bacteria, bifidobacteria, bacilli
What are prebiotics
A selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the GI microflora that confers benefits upon host well-being and health. Examples: inulin, oligofructose
Probiotics MOA
IBD may be associated with dysbiosis (an imbalance of intestinal microbial flora).
An imbalance may allow pathogens to invade the intestinal wall.
Probiotics introduce beneficial microorganisms.
Improve the balance of intestinal microflora.
Inhibit pathogens and toxin-producing bacteria.
May improve IBD.
Prebiotics MOA
Prebiotics provide substrates that are selectively fermented by intestinal microorganisms.
Change the composition and/or activity of intestinal microflora.
Promote beneficial effects on intestinal health.
Helminthic Therapy MOA
Absence of helminths (intestinal worms).
May contribute to abnormal intestinal immune regulation.
Leads to abnormal intestinal immune responses.
May contribute to bowel inflammation.
Helminthic therapy introduces controlled exposure to helminths.
May help regulate intestinal immune responses and reduce inflammation.
Supporting evidence: BD is much less in developing world where the parasite is common. Mutualism vs parasitism. Clinical data showed efficacy in patients with the therapy